Hormonal
Adjunctive use of GLP-1 receptor agonists (specifically liraglutide, semaglutide, and tirzepatide) in adults with Type 1 Diabetes significantly improves glycemic control, reduces total daily insulin doses, and promotes weight loss compared to placebo, without increasing the risk of severe hypoglycemia.
If you have Type 1 Diabetes and struggle with weight or high insulin doses, ask your doctor about adding a GLP-1 medication like semaglutide or liraglutide. These drugs can help lower your blood sugar, reduce the amount of insulin you need, and help you lose weight. Be aware that you might experience stomach upset, but starting with a low dose and increasing slowly can help manage this. This is an off-label use for T1D, so discuss the risks and benefits with your healthcare provider.
Semaglutide and other GLP-1 RAs showed significant improvements in glycemic outcomes, hemoglobin A1c levels, reduced insulin doses, and notable weight loss... Despite these challenges, GLP-1 RAs offer significant therapeutic benefits, making them a promising adjunct to insulin therapy for improving clinical outcomes in T1D management.
Why this rating
Based on multiple randomized controlled trials (Adjunct 1, Adjunct 2, STEP-1, SELECT) and meta-analyses, though some studies are short-term or off-label.
Source
The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists
Sujatha Seetharaman et al. · Journal of Diabetes Science and Technology · 2024
DOI 10.1177/19322968241309896
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →